PMID- 36044298
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230918
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 45
IP  - 2
DP  - 2023 Mar 1
TI  - Clinical and Cytogenetic Characteristics of Children With Leukemia 20-Year 
      Retrospective Study.
PG  - e161-e166
LID - 10.1097/MPH.0000000000002529 [doi]
AB  - Acute leukemias are the most common malignant diseases in childhood. The aims of 
      this retrospective cohort study were to investigate the frequency of cytogenetic 
      abnormalities in acute pediatric leukemia; the correlation between cytogenetic 
      abnormalities and 5-year survival; and the correlation between cytogenetic 
      abnormalities and clinical and laboratory features. We included 105 patients; 
      acute lymphoblastic leukemia (ALL) had 80.9% patients, B-cell lineage ALL (B-ALL) 
      84.7% of them, and T-cell lineage (T-ALL) 15.3%. The overall 5-year survival for 
      B-ALL was 85.9% and for T-ALL was 84.6%. The most common cytogenetic 
      abnormalities in patients with B-ALL were t(12;21)(p13.2;q22.1); ETV6-RUNX1 with 
      22.2% and hyperdiploidy with 19.4%. Our survival analysis showed that 
      t(12;21)(p13.2;q22.1); ETV6-RUNX1 and t(1;19)(q23;p13.3); TCF3-PBX1 had the best 
      5-year survival with 100% of patients surviving, whereas t(v;11q23.3); KMT2A 
      rearranged had the worst 5-year survival of just 33.3% of patients surviving 
      after 5 years. We found no difference in 5-year survival in B-ALL when comparing 
      clinical features. Acute myelogenous leukemia had 20 patients with 70.6% 5-year 
      survival. The most common cytogenetic abnormality in acute myelogenous leukemia 
      was t(8;21)(q21;q22.1); RUNX1-RUNX1T1 (20%). In conclusion, this study showed the 
      correlation of different cytogenetic abnormalities with 5-year survival in B-ALL 
      patients. Such correlation was not found when comparing clinical features and 
      5-year survival of patients with B-ALL. This emphasized the significance of 
      cytogenetic analysis in pediatric leukemia.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Runjic, Edita
AU  - Runjic E
AD  - Department of Pediatrics, University Hospital Split.
FAU - Jelicic Kadic, Antonia
AU  - Jelicic Kadic A
AD  - Department of Pediatrics, University Hospital Split.
FAU - Bastian, Lorenz
AU  - Bastian L
AD  - School of Medicine, University of Split, Split, Croatia.
FAU - Lozic, Mirela
AU  - Lozic M
AD  - School of Medicine, University of Split, Split, Croatia.
FAU - Buljubasic Soda, Maja
AU  - Buljubasic Soda M
AD  - Department of Pediatrics, University Hospital Split.
FAU - Petrovic, Marija
AU  - Petrovic M
AD  - Department of Pediatrics, University Hospital Split.
FAU - Malic Tudor, Karolina
AU  - Malic Tudor K
AD  - Department of Pediatrics, University Hospital Split.
FAU - Kuljis, Dubravka
AU  - Kuljis D
AD  - Department of Pediatrics, University Hospital Split.
FAU - Armanda, Visnja
AU  - Armanda V
AD  - Department of Pediatrics, University Hospital Split.
FAU - Lozic, Bernarda
AU  - Lozic B
AD  - Department of Pediatrics, University Hospital Split.
AD  - School of Medicine, University of Split, Split, Croatia.
LA  - eng
PT  - Journal Article
DEP - 20220829
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
SB  - IM
MH  - Child
MH  - Humans
MH  - Retrospective Studies
MH  - Core Binding Factor Alpha 2 Subunit/genetics
MH  - *Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
MH  - Chromosome Aberrations
MH  - Translocation, Genetic
MH  - Cytogenetic Analysis
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
MH  - *Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics
MH  - *Leukemia, Myeloid, Acute/genetics
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/01 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/08/31 12:13
PHST- 2021/11/22 00:00 [received]
PHST- 2022/06/26 00:00 [accepted]
PHST- 2022/09/01 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/08/31 12:13 [entrez]
AID - 00043426-202303000-00013 [pii]
AID - 10.1097/MPH.0000000000002529 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2023 Mar 1;45(2):e161-e166. doi: 
      10.1097/MPH.0000000000002529. Epub 2022 Aug 29.